|
|
Web
|
Sipuleucel-T medical facts from Drugs.com
http://www.drugs.com/mtm/sipuleucel-t.html
Sipuleucel-T contains a protein that stimulates the body's immune system to help it respond against certain cancer cells. |
More from
 |
|
Sipuleucel-T - National Cancer Institute
http://www.cancer.gov/about-cancer/treatment/drugs/sipuleucel-T/
This page contains brief information about sipuleucel-T and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials. |
More from
 |
|
Sipuleucel-T - Chemotherapy Drugs - Chemocare
http://chemocare.com/chemotherapy/drug-info/SipuleucelT.aspx
Sipuleucel-T is the generic name for the trade name drug Provenge(R). |
More from
 |
|
sipuleucel-T
http://www.uwhealth.org/health/topic/multum/provenge/d07638a1.html
Before you are treated with sipuleucel-T, tell your doctor about all of your medical conditions, especially heart disease, asthma, COPD or other breathing problems, or if you have ever had a stroke. |
More from
 |
|
Provenge (Sipuleucel-T) - Description and Clinical Pharmacology
http://www.druglib.com/druginfo/provenge/description_pharmacology/
PROVENGE consists of autologous peripheral blood mononuclear cells, including antigen presenting cells (APCs), that have been activated during a defined culture period with a recombinant human protein, PAP-GM-CSF, consisting of prostatic acid phosphatase... |
More from
 |
|
Provenge New FDA Drug Approval ; CenterWatch
http://www.centerwatch.com/drug-information/fda-approved-drugs/dr...
The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations. |
More from
 |
|
Cost of PROVENGE (sipuleucel-T) ; Insurance Coverage Information
http://www.provenge.com/reimbursement.aspx
,Co-pay and travel assistance foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. |
More from
 |
|
Sipuleucel T
http://www.upmc.com/patients-visitors/education/cancer-chemo/Page...
Sipuleucel-T is used to treat cancer.It is given in your vein (IV). |
More from
 |
|
Dendreon Corporation Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium
http://www.biospace.com/News/dendreon-corporation-announces-prese...
The previously published intent to treat analysis, which is described in the Food and Drug Administration (FDA) approved prescribing information for PROVENGE, did not account for cross-over and demonstrated a 4.1 month median survival benefit (HR=0.775, ... |
More from
 |
|
Prostate Cancer Expert Presents PROVENGE (sipuleucel-T) in Seal Beach, CA
http://www.thefreelibrary.com/Prostate+Cancer+Expert+Presents+PRO...
APA style: Prostate Cancer Expert Presents PROVENGE (sipuleucel-T) in Seal Beach, CA - an Immunotherapy Designed for Advanced Prostate Cancer.. (n.d.) >The Free Library. (2014). |
More from
 | |
1
2
3
4
5
6
7
8
9
⇨ |
News
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Libertas Academia - Monday, July 19, 2021 |
Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration's Adverse Event Reporting System, 2010-2017
Jama Network - Wednesday, September 11, 2019 |
Postmarketing Analysis of Sipuleucel-T"The Importance of Real-World Data
Jama Network - Wednesday, September 11, 2019 |
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Nature - Sunday, April 14, 2019 |
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence
Sage Pub - Tuesday, August 9, 2016 |
Judge Clears Way for Dendreon to Auction Provenge
Wall Street Journal - Saturday, August 6, 2016 |
Sipuleucel-T for metastatic castration-resistant prostate cancer
Wiley - Thursday, June 23, 2016 |
Sipuleucel-T in prostate cancer: Indication of added benefit 24 Mar 20151
Medical News Today - Thursday, March 26, 2015 |
Valeant Pharmaceuticals Intl : PROVENGE(R) (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment ...
EIN News - Saturday, March 7, 2015 |
PROVENGE(R) (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent ...
EIN News - Saturday, March 7, 2015 |
Valeant Offers $296 Million for Dendreon's Prostate Cancer Drug Provenge
U.S. Food and Drug Administration - Friday, February 6, 2015 |
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE(R) (sipuleucel-T)
PR Newswire - Friday, January 30, 2015 |
Valeant to buy Dendreon's prostate cancer vaccine Provenge
Yahoo - Friday, January 30, 2015 |
NICE Declines Dendreon's Prostate Cancer Drug Provenge
U.S. Food and Drug Administration - Wednesday, January 21, 2015 |
No added benefit found for sipuleucel-T in prostate cancer
Medical News Today - Monday, January 12, 2015 |
Sipuleucel-T in prostate cancer: Added benefit is not proven
Science Daily - Sunday, January 11, 2015 |
|
|
|
Subtypes
Subscribe to 'Sipuleucel T' news
